G1 Therapeutics Inc., of Research Triangle Park, N.C., entered a clinical trial collaboration with Astrazeneca plc, of Cambridge, U.K., to test G1's CDK4/6 inhibitor, G1T-38 with Astrazeneca's EGFR tyrosine kinase inhibitor, Tagrisso (osimertinib), in patients with EGFR mutation-positive non-small-cell lung cancer.